<html>

<head>
<meta name="POSTED" content="20060306">

<link REL="stylesheet" HREF="http://www.fda.gov/cder/cderstyle.css">
<!-- *****ENTER TITLE THAT SOULD APPEAR IN BLUE BAR AT TOP OF BROWSER SCREEN **** -->
<meta name="AUTHOR" content="Cunningham R">
<meta name="DESCRIPTION" content="Frequently Asked Questions on Potassium Iodide (KI)">
<meta name="DIVISION" content="FDA/CDER/OTCOM/DLIS">
<meta name="GENERATOR" content="Microsoft FrontPage 5.0">
<meta name="ISSUED" content="2/14/2002">
<meta name="keywords" content="Frequently Asked Questions on Potassium Iodide (KI)">
<meta name="POSTER" content="Sally Winthrop">
<title>Frequently Asked Questions on Potassium Iodide (KI)</title>
<!-- ***** GO TO NEXT SET OF ASTERISKS FOR CATEGORY NAME **** -->

</head>

<body topmargin="0" bgcolor="#FFFFFF">
<div align="center"><center>

<table border="0" cellpadding="0" cellspacing="0" width="640">
  <tr>
    <td><p align="center"><font face="ms sans serif, verdana, helvetica, arial" size="1"
    color="#0080FF">U.S. Food and Drug Administration</font><font
    face="ms sans serif, verdana, helvetica, arial" size="-2"><font face="arial, verdana"
    size="-1" color="#CC0000"> &#149;</font> <font color="#0080FF">Center for Drug Evaluation
    and Research</font></font><a href="#top"><img src="../graphics/clear.gif" border="0" alt="Skip navigation" width="1" height="1"></a></td>
  </tr>
</table>
</center></div><font face="ms sans serif, verdana, helvetica, arial" size="-2"><div
align="center"><center>

<table border="0" cellpadding="0" cellspacing="0" width="720">
  <tr>
    <td width="174">
    <img src="../graphics/CDER-LogoNu1inch.JPG"
    alt="CDER - Center for Drug Evaluation and Research Logo" width="174" height="72"></td>
    </font><td background="../graphics/BG-Header1inch.JPG" width"505" valign="middle"
    align="center" width="100%"><p align="center" class="headertitle">Drug
    Information</td>
    <! -- ****ENTER Page Category (matching one of left-side buttons) ****
    <td>
  </tr>
</table>
</center></div>
<!--webbot bot="Include" U-Include="../templates/2ndrow-component.htm" TAG="BODY" startspan -->
<div align="center"><center>

<table width="700" cellspacing="1">
  <tr>
    <td width="336"><form action="http://google2.fda.gov/search?" method="Get" name="mainForm">
 				 <input type="hidden" name="client" value="FDA"> 
                 <input type="hidden" name="site" value="cder">  
                 <input type="hidden" name="output" value="xml_no_dtd">  
                 <input type="hidden" name="lr" value=""> <input type="hidden" name="proxystylesheet" value="FDA">   
                 	
 <P><font color="#0080FF" face="Arial" size="-1">
 <label for="EnterSearchText"><b>Search</b> </label>
 <input type="text" name="q" size=18 maxlength=256 value="" tabindex="1" id="EnterSearchText"></font>
	<INPUT input type="submit" name="sa" value=" Go" tabindex="2"></FORM>
    </td>
    <td align="center" valign="top"><map name="FPMap0_I1">
      <area href="/cder/index.html" alt="CDER Home" shape="rect" coords="8, 5, 92, 26">
      <area href="/cder/site/default.htm" alt="Site Information" shape="rect" coords="97, 6, 154, 26">
      <area href="/cder/comment.htm" alt="Comments and Feedback" shape="rect" coords="156, 7, 223, 26">
      <area href="/cder/whatsnew.htm" alt="What's New" shape="rect" coords="229, 7, 310, 27"></map>
    <img border="0" src="../graphics/cdernavbar.gif" usemap="#FPMap0_I1" align="right" alt="CDER Navigation Bar" width="322" height="36" ></td>
  </tr>
</table>
</center></div>
<!--webbot bot="Include" endspan i-checksum="58768" -->
<center>

<table border="0" cellpadding="5" cellspacing="0" width="720" bgcolor="#FFFFFF">
  <tr>
  <!-- BEGINNING OF AREA FOR PAGE TITLE AND HORIZONTAL LINE -->
    <td width="113" valign="top" align="center">
    <!--webbot bot="Include"
    U-Include="../templates/sidebar-component.htm" TAG="BODY" startspan -->

<p><MAP NAME="FrontPageMap_I2"><AREA SHAPE="RECT" COORDS="1, 262, 91, 311" HREF="../archives/default.htm" alt="CDER Archives"><AREA SHAPE="RECT" COORDS="1, 210, 91, 258" HREF="../audiences/default.htm" alt="Specific Audiences"><AREA SHAPE="RECT" COORDS="0, 156, 91, 205" HREF="../calendar/default.htm" alt="CDER Calendar"><AREA SHAPE="RECT" COORDS="2, 102, 91, 152" HREF="../regulatory/default.htm" alt="Regulatory Information"><AREA SHAPE="RECT" COORDS="3, 51, 91, 99" HREF="../drug/default.htm" alt="Drug Information"><AREA SHAPE="RECT" COORDS="4, 0, 90, 47" HREF="../about/default.htm" alt="About CDER"></MAP><img src="../graphics/sidebuttons.gif" alt="Side Navigational Buttons" border="0" ismap width="92" height="312" usemap="#FrontPageMap_I2"></p>
<!--webbot bot="Include" endspan i-checksum="11423" -->

</td>
    <td width="551" align="left" valign="top" bgcolor="#FFFFFF"><h2 align="center" class="doctitle"><a name="top"></a><! -- **** ENTER TITLE FOR BODY OF PAGE **** --><b><font FACE="Times New Roman" SIZE="+1"><a name="up">Frequently</a>
      Asked Questions on Potassium Iodide (KI)</font></b></h2>
    <hr color="#004080">
      <p>In December 2001, the Food and Drug Administration (FDA) issued a final
      &quot;<a href="http://www.fda.gov/cder/guidance/4825fnl.htm">Guidance on
      Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies</a>.&quot;
      The objective of the document is to provide guidance to other Federal
      agencies, including the Environmental Protection Agency (EPA) and the
      Nuclear Regulatory Commission (NRC), and to state and local governments
      regarding the safe and effective use of potassium iodide (KI) as an
      adjunct to other public health protective measures in the event that
      radioactive iodine is released into the environment. The adoption and
      implementation of the recommendations are at the discretion of the state
      and local governments responsible for developing regional
      emergency-response plans related to radiation emergencies. The
      recommendations in the guidance address KI dosage and the projected
      radiation exposure at which the drug should be used. This guidance updates
      FDA’s 1982 recommendations.</p>
      <hr color="#000080">
      <ol>
        <li><a href="#KI do">What does potassium iodide (KI) do?</a></li>
        <li><a href="#Can KI be used">Can potassium iodide
          ( KI) be used to protect against
          radiation from bombs other than radioactive iodine?</a></li>
        <li><a href="#Who really needs">Who really needs to take potassium
          iodide (KI) after a nuclear radiation release?</a></li>
        <li><a href="#What potassium">What potassium iodide (KI) products are
          currently available?</a>&nbsp; </li>
        <li><a href="#products available">How are these products available?</a></li>
        <li><a href="#What dosages">What dosages of&nbsp; potassium iodide ( KI)
          should be taken for specific exposure levels?</a></li>
        <li><a href="#How long">How long should potassium
          iodide ( KI) be taken?</a></li>
        <li><a href="#Who should not take">Who should not take potassium
          iodide ( KI) or have
          restricted use?</a></li>
        <li><a href="#possible risks">What are the possible risks and side
          effects of taking potassium iodide ( KI)?</a></li>
        <li><a href="#Should I check">Should I check with my doctor first?</a></li>
        <li><a href="#As a doctor,">As a doctor, should I be recommending potassium
          iodide ( KI) for
          my patients who request it?</a></li>
        <li><a href="#buy KI">Should I go out and buy potassium
          iodide ( KI) to keep on hand?</a></li>
        <li><a href="#How do I know">How do I know that potassium
          iodide ( KI) will be available in
          case of an emergency?</a></li>
      </ol>
      <p><b><font face="Times New Roman">1.&nbsp; What does <a name="KI do">potassium
      iodide (KI) do</a>?</font></b></p>
      <p>The effectiveness of KI as a specific blocker of thyroid radioiodine
      uptake is well established. When administered in the recommended dose, KI
      is effective in reducing the risk of thyroid cancer in individuals or
      populations at risk for inhalation or ingestion of radioiodines. KI floods
      the thyroid with non-radioactive iodine and prevents the uptake of the
      radioactive molecules, which are subsequently excreted in the urine.</p>
      <p><b><font face="Times New Roman">2.&nbsp; <a name="Can KI be used">Can
      potassium iodide (KI) be used</a> to protect against radiation from bombs other than radioactive
      iodine?</font></b></p>
      <p>Potassium iodide ( KI)<font FACE="Times New Roman"> works only to prevent
      the
      thyroid from uptaking radioactive iodine. It is not a general radioprotective agent.</font></p>
      <p><font face="Times New Roman"><b>3.&nbsp; <a name="Who really needs"> Who
      really needs</a>  to take potassium iodide (KI) after a nuclear radiation
      release?</b></font></p>
      <p><font FACE="Times New Roman">The FDA guidance prioritizes groups based on age,
      <font color="#000000">which primarily determines</font>
      risk for radioiodine-induced thyroid cancer.&nbsp; Those at highest risk are
      infants and children, as well as pregnant and nursing females, and the recommendation is to<font color="#008080"> </font><font color="#000000">treat
      them at the</font> lowest
      threshold (with respect to predicted radioactive dose to the thyroid).&nbsp;
      Anyone over
      age 18 and up to age 40<font color="#000000"> should be treated at</font> a slightly higher
      threshold.&nbsp; Finally, anyone over 40 <font color="#000000">should be treated with KI only if th</font>e predicted exposure is high
      enough to destroy the thyroid and induce lifelong hypothyroidism (thyroid
      deficiency).</font></p>
      <p><b><font face="Times New Roman">4.&nbsp; <a name="What potassium">What
      potassium</a> iodide (KI) products are currently available?&nbsp;</font></b></p>
      <p><font face="Times New Roman">As of January 2005, Iosat, ThyroSafe, and 
      ThyroShield are FDA approved KI products. You can find out more about 
      these products at
      <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda">Drugs@FDA</a>. 
      Please be aware that only the KI products approved by FDA may be legally 
      marketed in the United States.</font></p>
      <p><font color="#ff0000" align="center"><b>
      <img alt="Back to Top" src="../graphics/up.gif" width="24" height="18"><small>
      </small></b></font><small><a href="#up">Back to Top</a></small></p>
      <p><b><font FACE="Times New Roman">5.&nbsp; How are these <a name="products available">products
      available</a>?</font></b></p>
      <p><font face="Times New Roman">In addition to distributing to state, 
      local and federal agencies, Anbex, Inc., has made Iosat Tablets (130 mg) 
      available to the general public via the Internet. For further information 
      on KI products, you can contact these companies as noted below:</font></p>
      <ul>
        <li><font face="Times New Roman">Anbex, Inc. for Iosat Tablets (130 mg) 
        at 212-580-2810 (M-F 9am-5pm), at 1-866-463-6754 (other times), or via 
        Internet <a href="http://www.anbex.com">http://www.anbex.com</a>. 
        [external link]</font></li>
        <li><font face="Times New Roman">Recip for ThyroSafe Tablets (65 mg) at 
        1-866-849-7672 or via the Internet
        <a href="http://www.thyrosafe.com/recip.html">
        http://www.thyrosafe.com/recip.html</a> [external link]</font></li>
        <li><font face="Times New Roman">Fleming &amp; Company, Pharmaceuticals for 
        ThyroShield Solution at 636-343-8200 or via the Internet
        <a href="http://www.flemingcompany.com">http://www.flemingcompany.com</a> 
        [external link], or <a href="http://www.thyroshield.com/">
        http://www.thyroshield.com/</a> [external link]</font></li>
    </ul>
      <p><b><font FACE="Times New Roman">6.&nbsp; <a name="What dosages">What
      dosages </a>of potassium iodide (KI) should be taken for specific exposure
      levels?</font></b></p>
      <p><font FACE="Times New Roman">Exposures greater than 5 cGy:&nbsp;&nbsp;&nbsp;<br>
      &nbsp;&nbsp;&nbsp; Birth through 1 mo.&nbsp; - 16 mg.<br>
      </font>&nbsp;&nbsp;&nbsp; <font FACE="Times New Roman">1 mo. through 3
      yrs.&nbsp; - 32 mg.<br>
      </font>&nbsp;&nbsp;&nbsp; <font FACE="Times New Roman">3 yrs through 18
      yrs.&nbsp; - 65 mg. (Adolescents&gt;150 pounds should take adult dose.)</font></p>
      <p><font FACE="Times New Roman">Exposures greater than 10 cGy:&nbsp;<br>
      &nbsp;&nbsp;&nbsp; 18 yrs through 40 yrs. - 130 mg</font></p>
      <p><font FACE="Times New Roman">Exposures greater than 500 cGy:&nbsp;<br>
      &nbsp;&nbsp;&nbsp; Adults over 40 yrs - 130 mg.</font></p>
      <p><font color="#ff0000" align="center"><b>
      <img alt="Back to Top" src="../graphics/up.gif" width="24" height="18"><small>
      </small></b></font><small><a href="#up">Back to Top</a></small></p>
      <p><b><font FACE="Times New Roman">7.&nbsp; <a name="How long">How long </a>should
      potassium iodide (KI) be taken?</font></b></p>
      <p><font FACE="Times New Roman">Since KI protects for approximately 24
      hours, it should be dosed daily until the risk no longer exists.&nbsp; Priority
      with regard to evacuation and sheltering should be given to pregnant
      females and neonates because of the potential for KI to suppress thyroid
      function in the fetus and neonate.&nbsp; Unless other protective
      measures are not available, we do not recommend repeat dosing in pregnant
      females and neonates.</font></p>
      <p><b><font FACE="Times New Roman">8.&nbsp; <a name="Who should not take">Who
      should not take</a> potassium iodide (KI) or have restricted use?</font></b></p>
      <p><font FACE="Times New Roman">Persons with known iodine sensitivity
      should avoid KI, as should individuals with dermatitis herpetiformis and
      hypocomplementemic vasculitis, extremely rare conditions associated with
      an increased risk of iodine hypersensitivity. Individuals with
      multinodular goiter, Graves' disease, and autoimmune thyroiditis should be
      treated with caution -- especially if dosing extends beyond a few days.</font></p>
      <p><b><font FACE="Times New Roman">9.&nbsp; What are the <a name="possible risks">possible
      risks</a> and side effects of taking potassium iodide (KI)?</font></b></p>
      <p><font FACE="Times New Roman">Thyroidal side effects of KI at
      recommended doses rarely occur in iodine-sufficient populations such as
      the U.S. As a rule, the risk of thyroidal side effects is related to dose
      and to the presence of underlying thyroid disease (e.g., goiter,
      thyroiditis, Graves').&nbsp; FDA recommends adherence to the <a href="http://www.fda.gov/cder/guidance/4825fnl.htm#KI Use in Radiation Emergencies: Treatment Recommendations"> Guidance</a> for
      intervention threshold and dose, though we recognize that the exigencies
      of any particular emergency situation may mandate deviations from those
      recommendations. With that in mind, it should be understood that as a
      general rule, the risks of KI are far outweighed by the benefits with
      regard to prevention of thyroid cancer in susceptible individuals.</font></p>
      <p><b><font face="Times New Roman">10.&nbsp; <a name="Should I check">Should
      I check</a> with my doctor first?</font></b></p>
      <p><font face="Times New Roman">P</font>otassium iodide (KI)<font FACE="Times New Roman"> is available
      over-the-counter (OTC).&nbsp; However,
      if you have any health concerns or questions, you should check with your
      doctor.</font></p>
      <p><font color="#ff0000" align="center"><b>
      <img alt="Back to Top" src="../graphics/up.gif" width="24" height="18"><small>
      </small></b></font><small><a href="#up">Back to Top</a></small></p>
      <p><b><font FACE="Times New Roman">11.&nbsp; <a name="As a doctor,">As a
      doctor,</a> should I be recommending potassium iodide (KI) for my patients who request it?</font></b></p>
      <p><font FACE="Times New Roman">As with any drug, physicians should
      understand the risks and benefits of KI before recommending it or
      prescribing it to patients. We recommend that physicians read our guidance
      for more information. It is available on the FDA website at </font><font FACE="Times New Roman" COLOR="#0000ff"><!-- TRANSIT - HYPERLINK -->
      <!-- .http://www.fda.gov/cder/guidance/index.htm. -->
      <a HREF="http://www.fda.gov/cder/guidance/index.htm">http://www.fda.gov/cder/guidance/index.htm</a></font><font FACE="Times New Roman">
      under procedural guidance #18. The FDA guidance discusses the rationale
      and methods of safe and effective use of KI in radiation emergencies. It
      specifically addresses threshold predicted thyroid radioiodine exposure
      for intervention and dosing by age group. The recommendations for
      intervention are based on categories of risk for thyroid cancer, with the
      young prioritized because of increased sensitivity to the carcinogenic
      effects of radioiodine.</font></p>
      <p><b><font FACE="Times New Roman">12.&nbsp; Should I go out and <a name="buy KI">buy
      potassium iodide </a>(KI) to keep on hand?</font></b></p>
      <p><font FACE="Times New Roman">KI works best if used within 3-4 hours of
      exposure. Although FDA has not made specific recommendations for
      individual purchase or use of KI, the Nuclear Regulatory Commission has contracted to purchase KI
      for states with nuclear reactors and states that have population within
      the 10-mile emergency planning zone, e.g., Delaware or West Virginia.</font></p>
      <p><b><font FACE="Times New Roman">13.&nbsp; <a name="How do I know">How
      do I know</a> that potassium iodide (KI) will be available in case of an emergency?</font></b></p>
      <p><font FACE="Times New Roman">FDA will continue to work with interested
      pharmaceutical manufacturers to assure that high quality, safe, and
      effective KI products are available for purchase by consumers, by state
      and local authorities, and by federal government agencies electing to do
      so.</font></p>
    <p align="center">
    <img src="../graphics/totop.gif" alt="totop.gif (1525 bytes)" width="23" height="36"> <a
    href="#top">Back to Top</a><!-- ****START of OPTIONAL "Back to Parent Page" link.  If this is not needed, 
    delete code between theis instruction and marker for the end of the optional link. --> &nbsp; 
    <img alt="Back" src="../graphics/backarrow8.GIF" width="25" height="30">
    <!-- **** Enter URL for Parent Page in following tag **** -->&nbsp; <a href="default.htm">Drug
    Preparedness and Response</a></p>
    <p align="left"><strong><small>FDA/Center for Drug Evaluation and Research<br>
    Last Updated: March 6, 2006<br>
    Originator: OTCOM/DLIS<br>
    <! -- **** ENTER YOUR INITIALS HERE **** -->
    HTML by </small><small>CSA, SJW</small></strong></td>
  </tr>
</table>
</center>
</body>
</html>